Utility scores in patients with MS
| Utility (SD) | Importance (relative) | Importance (averaged) | |
|---|---|---|---|
| Preventing relapse | |||
| Presenting a relapse every 2 years | −0.367 (0.131) | 8.3 | 10.4 |
| Presenting a relapse every 5 years | 0.367 (0.131) | ||
| Preventing disease progression | |||
| Preventing the disease from getting worse/progressing for 2 years | −0.445 (0.131) | 10.0 | 11.1 |
| Preventing the disease from getting worse/progressing for 5 years | 0.445 (0.131) | ||
| Side effect risk | |||
| Rare but severe, life-threatening side effects | −1.457 (0.131) | 32.9 | 26.5 |
| Frequent but mild/moderate side effects | 1.457 (0.131) | ||
| Route of administration | |||
| Oral | 1.345 (0.195) | 26.1 | 25.1 |
| Subcutaneous–intramuscular | −0.381 (0.175) | ||
| Intravenous | −0.965 (0.195) | ||
| Frequency of administration | |||
| Daily | −0.877 (0.206) | 22.7 | 26.9 |
| Every 2 days—weekly | −0.527 (0.251) | ||
| Monthly | 0.267 (0.206) | ||
| Twice per year (Constant) | 1.137 (0.251) | ||
| 5.875 (0.133) | |||
MS, multiple sclerosis.